Investigating targeted therapy for breast cancer using specific antibodies and immune treatments
Immunologic aspects of targeted therapy of erbB tumors
This study is looking at how a mix of special treatments using antibodies and immune boosters can help stop breast cancer cells from growing and spreading, using mice that act like humans with breast cancer, to find better ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10358586 on NIH RePORTER |
What this research studies
This research explores how a combination of targeted therapies using monoclonal antibodies and immune treatments can change the behavior of breast cancer cells. By using specially designed mice that mimic human breast cancer, the study aims to understand how these therapies can work together to prevent tumor growth and resistance. The approach involves administering a specific antibody followed by an immune molecule called IFN-γ to see how this affects tumor development and spread. The goal is to develop more effective treatments for breast cancer that can overcome resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer, particularly those whose tumors express the erbB2 oncoprotein.
Not a fit: Patients with non-breast cancer tumors or those whose tumors do not express the erbB2 oncoprotein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for breast cancer, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown promise in using targeted therapies and immune treatments together, suggesting that this approach could be effective.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Greene, Mark I — University of Pennsylvania
- Study coordinator: Greene, Mark I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.